Novavax Global Commercial Operations and COVID-19 Vaccine Update

Demonstrating variant strain change capabilities Preparing to supply monovalent or bivalent variant vaccine for fall 2023 vaccination season Strategy for Emerging Variants novavax Phase 3 COVID-19 Omicron Trial Initial Results • BA.1 vaccine candidate met primary strain-change endpoint, demonstrating ability to develop variant vaccines NVX-COV2373 induced broad immune response against original Wuhan, BA.1, and BA.5 strains . Next Steps Proactively monitoring emerging variants Developing vaccine candidates against emerging variants Execute part 2 of Phase 3 COVID-19 Omicron trial to evaluate BA.5 vaccine File for regulatory authorization Priority #1 © 2023 NOVAVAX. All rights reserved. 15

View entire presentation